Tüdőrák: vizsgálatok itt: Franciaország

In Franciaország 315 Also abroad 2744

315 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.

1/2. fázisTaking people
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Where
Lyon, Marseille, Villejuif Cedex
Életkor
18 év and over
People
55 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00
1. fázisNot yet taking people in Franciaország
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Lyon, Saint-Herblain, Toulouse, Villejuif
Életkor
18 év and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
3. fázisNot yet taking people in Franciaország
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
Where
Amiens, Caen Cedex 5, Créteil, Limoges, Montpellier Cedex 5, Paris, Rennes Cedex 9, Villejuif
Életkor
18 év and over
People
95 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2026-526300-67-00
No phaseTaking people
Analysis of Circulating Tumor Markers in Blood
Where
Montpellier
Életkor
18 év and over
People
992
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04025541
3. fázisTaking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Avignon, Bayonne, Bordeaux Cedex, Brest Cedex 2, Dijon, Le Mans Cedex 9, Lille, Marseille, Paris, Pierre-Bénite, Toulon, Toulouse, Vandoeuvre Les Nancy Cedex
Életkor
18 év and over
People
1000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
3. fázisTaking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Caen, Lille, Lyon, Paris Cedex 13, Saint-Herblain Cedex, Tours, Villejuif
Életkor
18 év and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
1/2. fázisTaking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Brest, Bron, Grenoble Cedex 9, Limoges
Életkor
18 év to 64 év
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
2. fázisTaking people
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Where
Lyon, Paris
Életkor
18 év and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00
3. fázisTaking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Clermont-Ferrand, Dijon, Paris, Pessac, Rennes, Suresnes, Toulouse, Vandoeuvre Les Nancy
Életkor
18 év and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Avignon, Bron, Caen Cedex 5, Clermont Ferrand Cedex 1, Lyon, Montpellier Cedex 5, Quimper Cedex, Reims Cedex, Saint-Herblain, Strasbourg Cedex, Suresnes, Villejuif
Életkor
18 év and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
3. fázisTaking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Avignon Cedex 9, Boulogne-Billancourt, Bron, Caen Cedex 5, Caen Cedex 9, Créteil, Dijon, Le Mans Cedex 9, Lyon, Lyon Cedex 04, Marseille, Nice Cedex 2, Paris, Pessac, Pierre-Bénite, Quimper Cedex, Rennes, Saint-Herblain, Saint-Herblain Cedex, Suresnes, Valenciennes, Villefranche Sur Saone Cedex, Villejuif
Életkor
18 év and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
1/2. fázisTaking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Lyon, Saint-Herblain, Toulouse Cedex 9, Villejuif
Életkor
12 év and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
3. fázisTaking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Bayonne, Besancon Cedex, Boulogne-Billancourt, Brest, Caen Cedex 9, Chambéry, Créteil, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Lille, Marseille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Nîmes, Orleans Cedex 2, Paris, Paris Cedex 14, Paris Cedex 20, Pessac, Poitiers, Quimper Cedex, Reims Cedex, Rennes, Rouen Cedex, Saint-Grégoire, Saint-Priest-en-Jarez, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Toulouse Cedex 3, Tours Cedex 9, Villefranche sur Saône, Villejuif
Életkor
18 év to 100 év
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
3. fázisTaking people
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Where
Angers, Bordeaux, Le Mans Cedex 9, Lyon, Vantoux
Életkor
18 év and over
People
290 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00
3. fázisTaking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Bordeaux, Brest, Bron, Creteil Cedex, Grenoble Cedex 9, Lille, Lyon, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 18, Rennes Cedex 9, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Toulouse, Villejuif
Életkor
18 év and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
No phaseTaking people
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
Where
Montpellier
Életkor
18 év and over
People
620
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT07060950
No phaseTaking people
Development of Clinical and Biological Database on Bronchial Cancer
Where
Montpellier
Életkor
18 év and over
People
750
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT07085429
2. fázisTaking people
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Where
Bordeaux, Dijon, Lyon, Paris, Suresnes
Életkor
18 év and over
People
105 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00
1/2. fázisTaking people
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Where
Dijon, Marseille
Életkor
18 év and over
People
315 worldwide
Run by
Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00
No phaseNot yet taking people in Franciaország
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Where
Pierre-Bénite
Életkor
50 év to 74 év
People
5400
Run by
Hospices Civils de Lyon
See details and how to joinNCT07921719
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Angers, Bobigny, Bron, Caen, Lyon, Montpellier, Nice, Paris, Pessac, Reims, Saint-Quentin, Strasbourg, Vannes
Életkor
18 év and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
3. fázisTaking people
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
Where
Avignon, Caen, Creil, Lille, Lyon, Nice, Nîmes, Paris, Saint-Cloud, Tarbes, Villejuif
Életkor
18 év and over
People
124
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT06840782
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Bordeaux, Brest, Grenoble Cedex 9, Lille, Marseille, Nantes Cedex 1, Paris, Paris Cedex 20, Rennes, Rouen, Toulouse, Villejuif
Életkor
18 év and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Bordeaux, Dijon, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Paris, Saint-Herblain, Toulouse, Villejuif
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
1/2. fázisTaking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Lille, Lyon, Marseille, Saint-Herblain, Villejuif
Életkor
18 év and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00